secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2024-09-27T23:59:59+00:00
Accession:  0001477932-24-005988
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx enters CEO employment agreement with Dr. Michel for Belgian subsidiary; consulting fee amended
--------------------------------------------------------------------------------

- Employment agreement with Dr. Gaetan Michel as CEO of Belgian Volition, effective Sept 1, 2024, with €12,000/month salary plus 13th month bonus.
- Consulting agreement amendment with 3F Management SRL increases monthly fee to €15,598 from Nov 1, 2024; variable bonus up to €26,390.
- Dr. Michel also serves as COO of parent, CEO of Volition America, and Manager of Volition Veterinary Diagnostics.
- Combined aggregate annual compensation is materially consistent with prior arrangements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793224005988/0001477932-24-005988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793224005988/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-24-005988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer